# Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

> **NCT05625087** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 162 (estimated)

## Conditions studied

- Breast Cancer Stage IV

## Interventions

- **DRUG:** Alpelisib
- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT05625087
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-19
- **Primary completion:** 2028-07
- **Final completion:** 2030-06
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2025-08-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05625087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05625087, "Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05625087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*